According to reports circulating last week, the Government is set to kick into the long grass the proposal for a national ...

Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of ...

Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...

BERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly ...

The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder ...

The 2025 ESMO annual meeting featured a urothelial carcinoma proffered paper session and a presentation by Dr. Maria De ...

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

AstraZeneca's Imfinzi with BCG delivers 32% lower recurrence risk in high-risk bladder cancer. Read more here.

Simple hysterectomy may result in little to no difference in the number of deaths from any cause, life expectancy after treatment, deaths from cancer, cancer-free period after treatment, or the rate ...

Medicaid expansion was associated with significantly improved 5-year cancer survival for patients in rural and high-poverty areas compared to non-expansion states. Five-year cause-specific survival ...

Deion Sanders faces another blood clot surgery, but the Colorado football coach said he plans to return to practice to ...